PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast - Monica Kraft, MD - The Latest Evidence on Treatment for Uncontrolled Persistent Asthma: Breaking News From Dallas

Monica Kraft, MD - The Latest Evidence on Treatment for Uncontrolled Persistent Asthma: Breaking News From Dallas

07/22/19 • 28 min

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Go online to PeerView.com/GSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses the latest evidence and data on treatment for persistent asthma presented at the American Thoracic Society Conference 2019 in Dallas, Texas. Upon completion of this activity, participants should be better able to: Discuss the latest clinical data for the efficacy and safety of approved and emerging treatments for uncontrolled persistent asthma, Employ strategies to treat patients with uncontrolled persistent asthma in the context of late-breaking data and patient-, disease-, and therapy-related factors.

Previous Episode

undefined - Ezra Cohen, MD, FRCPSC, FASCO - Mapping Progress With Immune Checkpoint Inhibitors in Head and Neck Cancer: Expert Views on Immunotherapy as a Component of Multimodal Care

Ezra Cohen, MD, FRCPSC, FASCO - Mapping Progress With Immune Checkpoint Inhibitors in Head and Neck Cancer: Expert Views on Immunotherapy as a Component of Multimodal Care

Go online to PeerView.com/XFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Already a cornerstone of care for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), immune checkpoint inhibitors are being explored in earlier treatment settings and in combination with other pillars of SCCHN care (such as surgery and radiotherapy). In this MasterClass activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 ASCO Annual Meeting, experts in head and neck (HNC) explore the evidence that is redefining the role of immunotherapy in HNC and offer insight on applications of new evidence on immunotherapy in HNC, as well as its future as a part of multimodal treatment plans. This activity also features a dedicated “Tumor Board” session designed to provide useful guidance on integrating checkpoint inhibitors into care—from the selection of upfront immunotherapy to the role of clinical trials as options for patients eligible for immune treatment. Upon completion of this activity, participants will be able to: Summarize evidence on the use of immune checkpoint inhibitors as single agents or in combination with other strategies in recurrent/metastatic, locally advanced, or resectable squamous cell carcinoma of the head and neck, Integrate immune checkpoint inhibitors into the treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck, including as upfront treatment or after progression on platinum chemotherapy, Identify patients with head and neck cancer who are eligible to receive immunotherapy as part of multimodal care across the disease spectrum, including in the context of a clinical trial, Manage immune-related adverse events in patients with squamous cell carcinoma of the head and neck receiving immunotherapy as single agents or in combination with other treatment modalities.

Next Episode

undefined - Nathan H. Fowler, MD - A MasterClass on Innovative Therapy in B-Cell Lymphoma: Evidence, Clinical Guidance, and Insights on the Future of Patient Care

Nathan H. Fowler, MD - A MasterClass on Innovative Therapy in B-Cell Lymphoma: Evidence, Clinical Guidance, and Insights on the Future of Patient Care

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.